Since both Barraud et al. and Espindola-Netto et al. showed that NAMPT inhibition could augment the sensitivity of pancreatic cancer cells to chemotherapeutic agents [11, 19], it would be interesting to determine if addition of NAMPT inhibitors to current systemic chemotherapy regimens could improve survival of pancreatic cancer patients stratified by tumor NAMPT expression. Here, NAMPT is linked to familial pancreatic carcinoma.